Ro(SSA) - 0.2mg

Ro(SSA) - 0.2mg

Regular price
$779.29
Regular price
Sale price
$779.29
Unit price
per 
Availability
Sold out

Ro RNP

SSA antigen
Ro60 antigen
Sjögren's syndrome antigen A
Uniprot ID:  F1MIZ7
mRNA RefSeq:  NM_001206183
Protein RefSeq:  NP_001193112
Size: 0.2mg
Source: Calf Thymus
Catalogue Number: ATR02-02

Product Information

Autoantibodies to the Ro(SSA) antigen are one of the most frequent serological markers of autoimmunity in rheumatic diseases. They are present in the serum of 50-80% of patients with Sjögren’s syndrome, 30-40% of patients with systemic lupus erythematosus (SLE), and 3-5% of patients with rheumatoid arthritis (RA). Ro(SSA) autoantibodies have also been reported in Sjögren’s syndrome-lupus overlap disease, subacute cutaneous lupus erythematosus, lupus with complement component deficiencies, neonatal lupus syndrome, multiple myeloma, polymyositis, progressive systemic sclerosis and primary biliary cirrhosis.

The incidence of anti-Ro (SSA) antibodies in the population of normal women of reproductive age is in the order of 1%. The presence of anti-La (SSB) autoantibodies usually coincides with the presence of anti-Ro (SSA).

Ro(SSA) antibodies target protein antigens associated with small RNA molecules known as hY-RNAs. These protein-RNA complexes are referred to as Ro-ribonucleoproteins (Ro-RNPs) and their biological function has yet to be elucidated. It is generally acknowledged that a 60kDa protein (Ro60) intimately associated with Ro-RNP constitutes the major Ro(SSA) antigen. The binding of autoantibodies to Ro60 is heterogenous: some sera recognise both the native and denatured antigen while others recognise the native antigen conformation only. The association of a second putative Ro(SSA) antigen of 52kDa (Ro52) with Ro-RNP remains unclear.

Although it has been proposed that Ro52 may be indirectly associated with Ro-RNP through Ro60, it has been conversely demonstrated that Ro52 does not copurify with Ro-RNPs during chromatographic separation. Furthermore true monospecific anti-Ro52 sera are known to be rare, they do not display a typical Ro(SSA) immunofluorescence pattern and are negative in immunodiffusion.
 

PDF-logo-dl Ro (SSA) datasheet

Clinical Indications

Sjögren's syndrome
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Neonatal Lupus Syndrome

MSDS

PDF-logo-dl  Material Safety Data Sheet

References

Tan, E.M. (1989) Adv. Immunol. 44, 93

McCauliffe, D.P. & Sontheimer, R.D. (1993) J. Inv. Dermatol. 100, 73

Harley, J.B. et al. (1986) Arthritis Rheum. 29, 196

Reichlin, M. (1986) J. Clin. Immunol. 6, 339

Boire, G. et al. (1993) J. Rheumatol. 20, 1654

Harley, J.B. et al. (1992) Rheum. Dis. Clin. N. America 18, 337

Calmes, M. & Bartholomew, B.A. (1985) J. Clin. Pathol. 38, 73

Taylor, P.V. et al. (1988) Br. J. Rheumatol. 27, 128

Craft, J.E. & Hardin, J.A. (1987) J. Rheumatol. 14 S13, 106

St. Clair, E.W. (1992) Rheum. Dis. Clin. N. America 18, 359

Hendrick, J.P. et al. (1981) Mol. Cell Biol. 1, 1138

Wolin, S.L. et al. (1984) 81, 1996

Chan, E.K.L. & Buyon, J.P. (1994) Man. Biol. Markers Dis.(Kluwer Acad. Publ.) B1/1-18

Boire, G. et al. (1991) Arthritis Rheum. 34, 722

Itoh, Y. & Reichlin, M. (1992) Autoimmunity 14, 57

Tsuzaka, K. et al. (1994) Arthritis Rheum. 37, 88

Slobbe, R.L. et al. (1992) J. Mol. Biol. 227, 361

Boire, G. et al. (1995) Clin. Exp. Immunol. 100, 489

Meheus, L. et al. (1998) 4th Dresden Symp. Autoantibodies (Abstract)

Deutscher, S.L. et al. (1988) Proc. Natl. Acad. Sci. USA 85, 9479

Ben-Chetrit, E. et al. (1989) J. Clin. Invest. 83, 1284

Wang, D. et al. (1996) Mol. Biol. Rep. 23, 205

Gaither, K.K. & Harley, J.B. (1985) Prot. Biol. Fluids Proc.Coll. 33, 413

Yamagata, H. et al. (1984) J. Clin. Invest. 74, 625

Yoshida, S. & Reichlin, M. (1990) J. Immunol. Methods 131, 113